Is Day One Biopharmaceuticals, Inc. (DAWN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 20.1% / 30% | 1.2% / 30% | 11.67% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 20.1% / 33% | 1.2% / 33% | 11.67% / 5% | ✗ NOT HALAL |
| MSCI | 0.6% / 33% | 86.9% / 33% | 5.3% / 33% | 11.67% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 20.1% / 33% | 1.2% / 33% | 11.67% / 5% | ✗ NOT HALAL |
| FTSE | 0.6% / 33% | 86.9% / 33% | 5.3% / 50% | 11.67% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 89.1% | |
| Operating Margin | -51.1% | |
| Net Margin | -67.8% | |
| Return on Equity (ROE) | -22.7% | |
| Return on Assets (ROA) | -14.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$104M |
| Free Cash Flow | -$108M |
| Total Debt | $3M |
| Debt-to-Equity | 0.6 |
| Current Ratio | 8.0 |
| Total Assets | $508M |
Price & Trading
| Last Close | $21.40 |
| 50-Day MA | $14.60 |
| 200-Day MA | $9.38 |
| Avg Volume | 4.4M |
| Beta | -1.3 |
|
52-Week Range
$5.63
| |
About Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Day One Biopharmaceuticals, Inc. (DAWN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Day One Biopharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Day One Biopharmaceuticals, Inc.'s debt ratio?
Day One Biopharmaceuticals, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.6%.
What are Day One Biopharmaceuticals, Inc.'s key financial metrics?
Day One Biopharmaceuticals, Inc. has a market capitalization of $2.2B, and revenue of $158M. The company maintains a gross margin of 89.1% and a net margin of -67.8%. Return on equity stands at -22.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.